1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow RET-positive Thyroid Cancer: new trials by email Literature Review of RET-positive Thyroid Cancer trials Research Report on RET-positive Thyroid Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer Alectinib - ALK-positive Non-small Cell Lung Cancer (NSCLC), RET-positive Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Terminated | Dana-Farber Cancer Institute | 5 | 2017-06-19 | 2021-09-27 |
Carcinoma, Non-Small-Cell Lung (1) · Thyroid Neoplasms (1)
Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Head and Neck Neoplasms (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1) · Thyroid Diseases (1)
alectinib (1)
Dana-Farber Cancer Institute (1)
United States (1)
Mark Awad, MD (1)